About this trial

Patient Profile

Advanced Colorectal Cancer with KRAS G12C mutation with disease progression on or after standard first line therapy

Where’s this trial being run?

Beaumont Hospital, Tallaght University Hospital, St Vincents University Hospital, Mater Misericordiae University Hospital, and Mater Private Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: KRYSTAL-10
Number: 21-06
Full Title:

A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy

Principal Investigator: Prof Ray McDermott
Type: Industry Sponsored

Mirati Therapeutics Inc

Recruitment Started: Global:
Global Recruitment Target: 420
Ireland Recruitment Target: 5